{"meshTags":["Antineoplastic Agents","Models, Molecular","Drug Resistance, Neoplasm","Cell Line, Tumor","Piperazines","Imatinib Mesylate","Small Molecule Libraries","Benzamides","Humans","Protein Transport","Protein Binding","Apoptosis","Pyrimidines","Proto-Oncogene Proteins c-abl","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","14-3-3 Proteins"],"meshMinor":["Antineoplastic Agents","Models, Molecular","Drug Resistance, Neoplasm","Cell Line, Tumor","Piperazines","Imatinib Mesylate","Small Molecule Libraries","Benzamides","Humans","Protein Transport","Protein Binding","Apoptosis","Pyrimidines","Proto-Oncogene Proteins c-abl","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","14-3-3 Proteins"],"genes":["c-Abl/14-3-3 protein-protein","14-3-3","c-Abl","c-Abl release from 14-3-3"],"organisms":["9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"An in silico structure-based ligand design approach resulted in the identification of the first non-peptidic small molecule able to inhibit protein-protein interactions between 14-3-3 and c-Abl. This compound shows an anti-proliferative effect on human leukemia cells either sensitive or resistant to Imatinib, in consequence of the T315I mutation. It also mediates c-Abl release from 14-3-3 in a way similar to that found in response to Imatinib treatment.","title":"Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis.","pubmedId":"20832303"}